TrumpRx ’s promised drug-price cuts expose a deeper systemic flaw, positioning direct-to-patient clinical pathways as the infrastructure pharma must build to turn political headlines into real access and outcomes.
Pouria Sanae
Advertisement
Co-founder and CEO, ixlayer
Articles by Pouria Sanae
Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be Applauded
Published: | Updated:
Physicians remain central even as DTP programs are implemented.
Advertisement
Latest Updated Articles
Engaging Patients: Why Pharma’s Direct-to-Patient Approach Should Be ApplaudedPublished: January 16th 2025 | Updated: February 13th 2025
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
FDA Approves Hernexeos Under National Priority Voucher Program
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
Leading in the Psychedelic Space: Q&A with Tarek Rabah
5